TABLE 6.
Characteristics of Patients on Antiviral Therapy and Both Detectable HBV RNA and Quantifiable HBV DNA by Aptima HBV, Ranked by Duration of Treatment
| Subject | Country of Origin | Age | HBeAg | NA | Duration of Therapy (Years) | HBV RNA log10 Copies/mL | HBV DNA (log10 IU/mL) | ||
|---|---|---|---|---|---|---|---|---|---|
| Aptima | Xpert | Cobas | |||||||
| M1 | Vietnam | 24 | + | TDF | 0.1 | 4.3 | 5.0 | 3.5 | 3.5 |
| M2 | China | 56 | + | TDF | 0.2 | 4.7 | 3.9 | 2.8 | 2.7 |
| M3 | Zambia | 26 | + | TDF | 0.3 | 8.6 | 9.4 | 9.5 | 9.6 |
| F1 | United Kingdom | 22 | + | ETV | 0.9 | 7.6 | 4.3 | 3.4 | 3.5 |
| M4 | United Kingdom | 24 | + | TDF | 1.1 | 7.4 | 3.4 | 3.0 | Not done |
| F2 | China | 29 | + | ETV | 2.3 | 7.0 | 3.5 | 3.2 | 3.3 |
| M5 | China | 37 | + | TDF | 2.8 | 6.0 | 2.3 | <LLOQ | <LLOQ |
| M6 | China | 38 | + | TDF | 3.1 | 5.6 | 2.6 | 2.0 | 2.1 |
| F3 | China | 35 | + | TDF | 4.1 | 5.8 | 1.9 | <LLOQ | <LLOQ |
| F4 | China | 33 | + | TDF | 4.1 | 4.8 | 2.4 | <LLOQ | <LLOQ |
Abbreviations: ETV, entecavir; F, female; M, male; TDF, tenofovir disoproxil fumarate.